Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

Autor: Saenz DT; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Fiskus W; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Manshouri T; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Mill CP; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Qian Y; Arvinas, Inc., 5 Science Park, New Haven, CT, 06511, USA., Raina K; Arvinas, Inc., 5 Science Park, New Haven, CT, 06511, USA., Rajapakshe K; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA., Coarfa C; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA., Soldi R; β Cat Pharma, 2450 Holcombe Blvd. Suite J606, Houston, TX, 77021, USA., Bose P; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Borthakur G; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Kadia TM; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Khoury JD; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Masarova L; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Nowak AJ; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Sun B; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Saenz DN; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Kornblau SM; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Horrigan S; β Cat Pharma, 2450 Holcombe Blvd. Suite J606, Houston, TX, 77021, USA., Sharma S; Translational Genomics Research Institute (TGen), 445 N. Fifth Street, Phoenix, AZ, 85004, USA., Qiu P; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, Atlanta, GA, 30332, USA., Crews CM; Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, 06520, USA.; Department of Chemistry, Yale University, New Haven, CT, 06520, USA.; Department of Pharmacology, Yale University, New Haven, CT, 06520, USA., Verstovsek S; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA., Bhalla KN; The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA. kbhalla@mdanderson.org.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2019 Jun; Vol. 33 (6), pp. 1373-1386. Date of Electronic Publication: 2018 Dec 21.
DOI: 10.1038/s41375-018-0334-3
Abstrakt: Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-catenin or treatment with BC2059 that disrupts binding of β-catenin to TBL1X (TBL1) depleted nuclear β-catenin levels. This induced apoptosis of not only JAKi-sensitive but also JAKi-persister/resistant post-MPN sAML BPCs, associated with attenuation of TCF4 transcriptional targets MYC, BCL-2, and Survivin. Co-targeting of β-catenin and JAK1/2 inhibitor ruxolitinib (rux) synergistically induced lethality in post-MPN sAML BPCs and improved survival of mice engrafted with human sAML BPCs. Notably, co-treatment with BET protein degrader ARV-771 and BC2059 also synergistically induced apoptosis and improved survival of mice engrafted with JAKi-sensitive or JAKi-persister/resistant post-MPN sAML cells. These preclinical findings highlight potentially promising anti-post-MPN sAML activity of the combination of β-catenin and BETP antagonists against post-MPN sAML BPCs.
Databáze: MEDLINE
Externí odkaz: